Literature DB >> 26958500

Necitumumab for first-line treatment of advanced, squamous, non-small-cell lung cancer: a relevant step forward?

Jon Zugazagoitia1, Santiago Ponce1, Luis Paz-Ares1.   

Abstract

Entities:  

Year:  2016        PMID： 26958500      PMCID： PMC4758970          DOI： 10.3978/j.issn.2218-6751.2015.08.05

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  14 in total

Review 1.  Complex decisions for first-line and maintenance treatment of advanced wild-type non-small cell lung cancer.

Authors:  Ryan D Gentzler; Melissa L Johnson
Journal:  Oncologist       Date:  2015-02-06

Review 2.  Squamous cell lung cancer: from tumor genomics to cancer therapeutics.

Authors:  David R Gandara; Peter S Hammerman; Martin L Sos; Primo N Lara; Fred R Hirsch
Journal:  Clin Cancer Res       Date:  2015-05-15       Impact factor: 12.531

Review 3.  Epidermal growth factor receptor-directed monoclonal antibodies in nonsmall cell lung cancer: an update.

Authors:  Robert Pirker
Journal:  Curr Opin Oncol       Date:  2015-03       Impact factor: 3.645

4.  Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer.

Authors:  Jean-Louis Pujol; Robert Pirker; Thomas J Lynch; Charles A Butts; Rafael Rosell; Frances A Shepherd; Johan Vansteenkiste; Kenneth J O'Byrne; Barbara de Blas; Jim Heighway; Anja von Heydebreck; Nick Thatcher
Journal:  Lung Cancer       Date:  2013-11-16       Impact factor: 5.705

5.  Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.

Authors:  Luis Paz-Ares; Jörg Mezger; Tudor E Ciuleanu; Jürgen R Fischer; Joachim von Pawel; Mariano Provencio; Andrzej Kazarnowicz; György Losonczy; Gilberto de Castro; Aleksandra Szczesna; Lucio Crino; Martin Reck; Rodryg Ramlau; Ernst Ulsperger; Christian Schumann; Jose Elias A Miziara; Álvaro E Lessa; Mircea Dediu; Beatrix Bálint; Henrik Depenbrock; Victoria Soldatenkova; Raffael Kurek; Fred R Hirsch; Nick Thatcher; Mark A Socinski
Journal:  Lancet Oncol       Date:  2015-02-18       Impact factor: 41.316

6.  Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancer.

Authors:  Federico Cappuzzo; Giovanna Finocchiaro; Francesco Grossi; Paolo Bidoli; Adolfo Favaretto; Antonio Marchetti; Maria Luisa Valente; Agnieszka Cseh; Laura Clementi; Dan Massey; Armando Santoro
Journal:  J Thorac Oncol       Date:  2015-04       Impact factor: 15.609

7.  Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8.

Authors:  Shiqing Li; Paul Kussie; Kathryn M Ferguson
Journal:  Structure       Date:  2008-02       Impact factor: 5.006

8.  Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

Authors:  Robert Pirker; Jose R Pereira; Aleksandra Szczesna; Joachim von Pawel; Maciej Krzakowski; Rodryg Ramlau; Ihor Vynnychenko; Keunchil Park; Chih-Teng Yu; Valentyn Ganul; Jae-Kyung Roh; Emilio Bajetta; Kenneth O'Byrne; Filippo de Marinis; Wilfried Eberhardt; Thomas Goddemeier; Michael Emig; Ulrich Gatzemeier
Journal:  Lancet       Date:  2009-05-02       Impact factor: 79.321

9.  Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.

Authors:  Thomas J Lynch; Taral Patel; Luke Dreisbach; Michael McCleod; William J Heim; Robert C Hermann; Eugene Paschold; Nicholas O Iannotti; Shaker Dakhil; Steven Gorton; Virginie Pautret; Martin R Weber; Donald Woytowitz
Journal:  J Clin Oncol       Date:  2010-01-25       Impact factor: 44.544

10.  A genomics-based classification of human lung tumors.

Authors: 
Journal:  Sci Transl Med       Date:  2013-10-30       Impact factor: 17.956
View more
  7 in total

Review 1.  Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?

Authors:  Georgios Tsironis; Dimitrios C Ziogas; Anastasios Kyriazoglou; Marita Lykka; Konstantinos Koutsoukos; Aristotelis Bamias; Meletios-Athanasios Dimopoulos
Journal:  Ann Transl Med       Date:  2018-04

Review 2.  New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib.

Authors:  Vera Hirsh
Journal:  Onco Targets Ther       Date:  2017-05-11       Impact factor: 4.147

3.  The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition.

Authors:  Justin Goodwin; Michael L Neugent; Shin Yup Lee; Joshua H Choe; Hyunsung Choi; Dana M R Jenkins; Robin J Ruthenborg; Maddox W Robinson; Ji Yun Jeong; Masaki Wake; Hajime Abe; Norihiko Takeda; Hiroko Endo; Masahiro Inoue; Zhenyu Xuan; Hyuntae Yoo; Min Chen; Jung-Mo Ahn; John D Minna; Kristi L Helke; Pankaj K Singh; David B Shackelford; Jung-Whan Kim
Journal:  Nat Commun       Date:  2017-05-26       Impact factor: 14.919

4.  Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung.

Authors:  Shun Lu; Wei Li; Caicun Zhou; Cheng-Ping Hu; Shukui Qin; Gang Cheng; Jifeng Feng; Jie Wang; Agnieszka Cseh; Barbara Peil; Neil Gibson; Eva Ehrnrooth; Li Zhang
Journal:  Onco Targets Ther       Date:  2018-11-30       Impact factor: 4.147

Review 5.  Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib.

Authors:  Shun Lu
Journal:  Onco Targets Ther       Date:  2019-02-22       Impact factor: 4.147

6.  Role of downregulated ADARB1 in lung squamous cell carcinoma.

Authors:  Xiang Wang; Xinxin Ren; Wanli Liu; Xi Chen; Jie Wei; Zhicheng Gong; Yuanliang Yan; Zhijie Xu
Journal:  Mol Med Rep       Date:  2020-01-23       Impact factor: 2.952

7.  Identification of key genes and evaluation of clinical outcomes in lung squamous cell carcinoma using integrated bioinformatics analysis.

Authors:  Yangfeng Shi; Yeping Li; Chao Yan; Hua Su; Kejing Ying
Journal:  Oncol Lett       Date:  2019-09-30       Impact factor: 2.967
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.